These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21848481)

  • 21. Antihypertensive effects of candesartan cilexetil, enalapril and placebo.
    Franke H
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S61-2. PubMed ID: 9331010
    [No Abstract]   [Full Text] [Related]  

  • 22. Candesartan cilexetil: an update.
    Joost A; Schunkert H; Radke PW
    Expert Opin Pharmacother; 2011 Aug; 12(11):1769-80. PubMed ID: 21651457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study.
    Rakugi H; Enya K; Sugiura K; Ikeda Y
    Hypertens Res; 2012 May; 35(5):552-8. PubMed ID: 22278628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan.
    Yasuno S; Fujimoto A; Nakagawa Y; Kuwahara K; Ueshima K
    Expert Rev Cardiovasc Ther; 2012 May; 10(5):577-83. PubMed ID: 22651833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design.
    Andersen NH; Knudsen ST; Poulsen PL; Poulsen SH; Helleberg K; Eiskjaer H; Hansen KW; Bek T; Mogensen CE
    J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):96-9. PubMed ID: 12806591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Angiotensin receptor antagonist for therapy of patients with hypertension].
    Rakugi H; Ogihara T
    Nihon Rinsho; 1997 Aug; 55(8):2075-80. PubMed ID: 9284426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension.
    Belcher G; Hübner R; George M; Elmfeldt D; Lunde H
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S85-9. PubMed ID: 9331017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
    Barrios V; Escobar C
    Expert Opin Pharmacother; 2013 Nov; 14(16):2249-61. PubMed ID: 24070321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Achieving quality 24-h blood pressure control with candesartan cilexetil.
    Meredith P
    Blood Press Suppl; 2000; 1():23-6. PubMed ID: 11059632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Organ protection in hypertensive type 2 diabetic patients. Double chance with AT1 blockers].
    MMW Fortschr Med; 2000 Jan; 142(3):58-9. PubMed ID: 10726465
    [No Abstract]   [Full Text] [Related]  

  • 32. Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.
    Plosker GL; Keam SJ
    Pharmacoeconomics; 2006; 24(12):1249-72. PubMed ID: 17129078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The CHARM programme raises the profile of candesartan cilexetil in the treatment of chronic health failure.
    Cardiovasc J S Afr; 2004; 15(1):42-3. PubMed ID: 15095753
    [No Abstract]   [Full Text] [Related]  

  • 34. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
    Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
    Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerability of a modern antihypertensive agent: candesartan cilexetil.
    Andersson OK
    Basic Res Cardiol; 1998; 93 Suppl 2():54-8. PubMed ID: 9833164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by home blood pressure in hypertensive patients.
    Imbs JL; Nisse-Durgeat S;
    Int J Clin Pract; 2005 Jan; 59(1):78-84. PubMed ID: 15707470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.
    Mallion JM; Goldberg AI
    Blood Press Suppl; 1996; 2():82-6. PubMed ID: 8913546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
    Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
    Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reducing cardiovascular morbidity and mortality in the elderly.
    Trenkwalder P
    Blood Press Suppl; 2000; 1():40-3. PubMed ID: 11059636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.